T he name "myeloid-derived suppressor cells" was introduced to scientific literature 10 years ago 1 and initially described a loosely defined group of myeloid cells with potent immuneregulatory activity. In recent years, the nature and biological role of MDSCs have become clearer, and MDSCs have emerged as a universal regulator of immune function in many pathologic conditions. MDSCs consist of two large groups of cells: granulocytic or polymorphonuclear MDSCs (PMN-MDSCs) and monocytic MDSCs (M-MDSCs). PMN-MDSCs are phenotypically and morphologically similar to neutrophils, whereas M-MDSCs are similar to monocytes 2 . Studies in humans demonstrated the existence of a third, small, population of MDSCs that includes cells with colony-forming activity and other myeloid precursors. These cells are currently termed early-stage MDSCs 3 and have yet to be defined in mice.
Intensive clinical studies identified MDSCs as a valuable predictive marker in cancer, and extensive efforts in MDSC targeting are ongoing. However, despite such advances, the nature of MDSCs still raises questions and skepticism. This Review is not a comprehensive analysis of MDSC phenotype or function (these topics have been addressed in many reviews in recent years 4, 5 ), but rather our attempt to address the most controversial issues pertinent to these cells. We discuss new information regarding development, activation status, phenotype and function that allows for better discrimination of MDSCs from other myeloid cells. We also discuss the role of MDSCs in the regulation of different pathologic conditions.
What are these cells?
The main controversial issue associated with MDSCs since their initial discovery has been their nature. Morphologically and phenotypically, MDSCs are similar to neutrophils and monocytes. What is so special about these cells that would justify their having a separate name? What makes these cells different? Below we present our view on why MDSCs are indeed a very special group of cells with unique features and biological roles.
The major populations of bone marrow (BM)-derived myeloid cells are granulocytes (with their most abundant representative, neutrophils) and mononuclear cells (monocytes, terminally differentiated macrophages and dendritic cells (DCs)). Unlike in experiments in vitro, in which both macrophages and DCs can be easily differentiated from monocytes, in tissues under steady-state conditions macrophages expand largely in situ, and most DCs differentiate from their specific BM precursors 6 . However, during inflammation and cancer, BM-derived monocytes are the primary precursors of macrophages, especially tumor-associated macrophages (TAMs) and a population of inflammatory DCs 7 .
Myeloid cells have emerged as a major contributor to protection against pathogens and are an important element of tissue remodeling. Under physiological conditions, the cell-signaling molecule GM-CSF drives myelopoiesis, and G-CSF and M-CSF induce the differentiation of granulocytes and macrophages, respectively 8 . In cancer and other pathological conditions, these factors are overproduced and favor the generation of MDSCs 2, 9 . Thus, accumulation of MDSCs takes place alongside the same differentiation pathways as for neutrophils and monocytes.
Classical activation of myeloid cells occurs in response to relatively strong signals from pathogens, primarily in the form of Tolllike receptor (TLR) ligands, various damage-associated molecular patterns, and pathogen-associated molecular pattern molecules 10 . This results in rapid mobilization of monocytes and neutrophils from the BM, a dramatic increase in phagocytosis, respiratory burst, the production of proinflammatory cytokines, and upregulation of major histocompatibility complex (MHC) class II and costimulatory molecules 11, 12 . This response is usually of short duration and ends in elimination of the threat. During unresolved inflammation such as in persistent infection, cancer and other chronic conditions, the nature of signals activating myeloid cells differs 13, 14 . These signals are relatively weak and of a long duration, and they often come in the form of growth factors and inflammatory mediators, as described in detail below. Neutrophils and monocytes generated under these conditions have an immature phenotype and morphology; relatively weak phagocytic activity; increased background levels of reactive oxygen species (ROS) and nitric oxide (NO) production; and high expression of arginase, PGE2 and a number of anti-inflammatory cytokines 15, 16 . Most of these features are absent in classically activated neutrophils and monocytes. Therefore, this state of activation can be characterized as pathologic (Fig. 1) . This pathologic activation state leads not to the elimination of the threat or activation of immunity, but to the inhibition of adaptive immunity (immune suppression) and support of tumor progression and metastasis. Cells in this pathologic state of activation can be identified functionally, biochemically and, to some extent, phenotypically, and are now collectively termed MDSCs. The longer the myeloid compartment is exposed to the effects of the factors described above, the more potent the pathologic activation of these MDSCs is in humans and mice. Therefore, at any given moment, there is a heterogeneous population of cells in tissues that includes classically activated neutrophils and monocytes, and pathologically activated Myeloid-derived suppressor cells coming of age Filippo Veglia, Michela Perego and Dmitry Gabrilovich* Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells generated during a large array of pathologic conditions ranging from cancer to obesity. These cells represent a pathologic state of activation of monocytes and relatively immature neutrophils. MDSCs are characterized by a distinct set of genomic and biochemical features, and can, on the basis of recent findings, be distinguished by specific surface molecules. The salient feature of these cells is their ability to inhibit T cell function and thus contribute to the pathogenesis of various diseases. In this Review, we discuss the origin and nature of these cells; their distinctive features; and their biological roles in cancer, infectious diseases, autoimmunity, obesity and pregnancy.
MDSCs (Fig. 2) . For instance, at early stages of cancer, bona fide immune-suppressive MDSCs are rarely detected. However, there are cells with some biochemical and genomic characteristics of MDSCs 5, 17, 18 that probably represent an intrinsic phase of MDSC development; they could be called MDSC-like cells (Fig. 2) . It may be possible for pathologic activation of MDSCs to be transferred via hematopoietic progenitor cells, as a sort of innate immune memory triggered by chronic inflammatory conditions through signals that interfere with transcription factors and epigenetic reprogramming 19 . Memory or trained immunity can rely on an altered functional state of immune cells that persists for weeks to months after the elimination of the initial stimulus. The true nature of this process in MDSCs needs to be elucidated.
The accumulation of MDSCs is a complex and gradual phenomenon governed by multiple factors. We previously suggested that accumulation of MDSCs depends on two groups of interconnected signals. The first group of signals is important for the expansion of populations of immature myeloid cells, whereas the second group is responsible for their pathologic activation 20 . The first group of signals is driven by factors produced by tumors or BM stroma in response to chronic infection and inflammation, and includes the following: GM-CSF, G-CSF, M-CSF, S-SCF, VEGF and polyunsaturated fatty acids [21] [22] [23] [24] . The transcriptional factors/regulators STAT3, STAT5, IRF8, C/EBP-β and NOTCH have a major role in this process 25 . Other factors involved in this process include adenosine receptor A2b, cytoplasmic receptor NLRP3, retinoblastoma protein 1 (RB1), and alarmins S100A9 and S100A8. Furthermore, a recent study showed that the antiapoptotic molecules c-FLIP and MCL-1 are involved in the development of M-MDSCs and PMN-MDSCs in cancer, respectively 26 . The second group of signals is mediated by inflammatory cytokines and damage-associated molecular patterns, including interferon-γ (IFN-γ ), IL-1β , IL-4, IL-6, IL-13, tumor necrosis factor (TNF), and the TLR ligand HMGB1. These factors mainly signal via NF-κ B, STAT1 and STAT6 25 . A recent study provided a direct experimental demonstration of this concept, showing that the licensing of monocytes with GM-CSF was required for subsequent IFN-γ -mediated conversion of these cells to immunesuppressive M-MDSCs 27 .
Phenotypic and molecular features of MDSCs
Another controversial issue that was apparent from the beginning is how to identify these cells. The field of MDSC research is still immature, and it is difficult to distinguish these cells from neutrophils and monocytes. In mice, PMN-MDSCs can be defined as CD11b + Ly6G + Ly6C lo cells with high side scatter 28 . This phenotype is typical for neutrophils, but in some experimental models PMNMDSCs can also express markers not normally present on neutrophils, such as CD115 and CD244 16 . Direct phenotypic distinction between mouse PMN-MDSCs and tumor-associated neutrophils (TANs) is even more difficult. TANs are a heterogeneous population of cells that includes neutrophils with antitumor properties and neutrophils with potent suppressive functions 29 . On the basis of these functional characteristics, it is likely that the second group of 'neutrophils' are in fact PMN-MDSCs [30] [31] [32] . However, this question cannot be resolved until specific markers of mouse PMN-MDSCs are identified.
M-MDSCs are defined as CD11b + Ly6G -Ly6C hi cells with low side scatter 28 . This is the classic phenotype of inflammatory monocytes present in healthy mice. Other typical markers shared by these cells include CD115, CCR2 and CD49d (VLA4) 33 . However, M-MDSCs usually lack surface markers of monocytes such as CD11c and MHC class II 22, 34 . Phenotypically, M-MDSCs can be readily separated from TAMs 2, 35 , as TAMs have high expression of F4/80, low to intermediate expression of Ly6C, and low or undetectable expression of S100A9 protein (Table 1) .
In humans, the equivalent of mouse PMN-MDSCs and M-MDSCs has been found in the low-density Ficoll-gradient fraction of peripheral blood mononuclear cells. In contrast, neutrophils are isolated from the high-density fraction. PMN-MDSCs and neutrophils share a similar phenotype: CD11b
However, different densities allow for the distinction of these cells (Table 1) 
CD33
+ , where Lin comprises CD3, CD14, CD15, CD19 and CD56 5, 37 . Thus, in humans, MDSCs can be separated from neutrophils and monocytes on the basis of phenotypic markers and density gradient, whereas in mice such distinction is much more challenging. This is probably due to differences between mouse models and human diseases. Most mouse cancer models involve the transplantation of tumor cells, which is associated with inflammation and rapid tumor progression. This leads to a dramatic expansion of MDSC populations that may replace most of the neutrophils and monocytes. This is not the case in human disease 38 . More detailed studies including single-cell sequencing may help to address this question.
Human PMN-MDSCs have a gene expression profile that distinguishes them from neutrophils in people with cancer, as well as those from healthy donors 36 . This includes eukaryotic translationinitiation factors 2 and 4 (eIF2 and eIF4), associated with endoplasmic reticulum (ER) stress (discussed below), and upregulation of mTOR signaling, the MAPK pathway, CSF1 and the IFN-γ -regulated pathways 36 . It is important to point out that none of these pathways by themselves can define MDSCs. cDNA array analyses of sorted mouse PMN-MDSCs and neutrophils showed that PMN-MDSCs have higher expression of genes associated with cell cycle, autophagy, G protein signaling and the CREB pathway 16 . Neutrophils, in contrast, have higher expression of genes associated with NF-κ B signaling via CD40, IL-1, IL-6, TLR and TNF pathways, as well as lymphotoxin-β -receptor signaling. Substantial differences between PMN-MDSCs from tumor-bearing mice and neutrophils from tumor-free mice have been identified via whole transcriptomic analysis 39 . Quantitative proteomics of mouse MDSCs determined that these cells constitute a distinct myeloid population characterized by a 'kinase signature' and well-defined interactomes 40, 41 . Thus, it seems that distinct genomic and proteomic signatures of MDSCs could be developed on the basis of the available information, but more formal validation studies are needed to establish their value. In addition to gene and protein expression profiles, MDSCs are distinguished from neutrophils and monocytes by the activity and expression of specific molecules. Upregulation of STAT3 is a hallmark of MDSCs, as this transcription factor is directly implicated in the accumulation of MDSCs in humans and mice 35, [42] [43] [44] . Interestingly, although STAT3 activity is critical for the expansion of MDSC populations in BM and spleen, inside tumors MDSCs seem to downregulate STAT3 activity via a mechanism that involves the hypoxia-inducible activation of CD45 phosphatase 45 . This promotes rapid differentiation of M-MDSCs to TAMs. Downregulation of IRF8, a member of the interferon-related factor (IRF) family, is closely associated with the expansion of PMN-MDSC populations in mice [28] [29] [30] . A very recent study showed that the growth of 4T1 mammary adenocarcinoma is associated with the selective population expansion of IRF8 lo granulocyte progenitors. These progenitors have an increased ability to form PMN-MDSCs 46 . Upregulation of C/EBP-β , a member of a family of basic-region leucine zipper transcription factors, is also associated with the expansion of MDSC populations 47 . C/EBP-β regulates the expression of arginase (ARG1) and inducible nitric oxide synthase (iNOS), which are required for the suppressive functions of MDSCs 48 . RB1 (p105) is a member of the RB family, as are RB2 (p130) and p107, which repress the transcription factor E2F and block cell proliferation. Low expression of RB1 in M-MDSCs is associated with these cells' ability to differentiate to PMN-MDSCs, whereas RB1 hi M-MDSCs give rise to macrophages and DCs 49 . The accumulation of RB1 lo PMN-MDSCs has also been described in the PyMT transgenic model of breast cancer 50 .
Immune-suppressive activity of MDSCs
Another controversial issue in MDSC biology is whether the functional activity of these cells is uniquely associated with a specific set of biochemical events. Immune suppression is the main feature of MDSCs that allows them to be distinguished from monocytes and neutrophils in peripheral blood in humans and in spleens of mice. Splenic monocytes in mice and monocytes isolated from peripheral blood of humans can acquire immune-suppressive features after several days of culture on plastic. This approach is used to generate MDSCs in vitro. However, although these in vitro-derived cells share suppressive activity and some suppressive mechanisms (such as those related to NO) with M-MDSCs, at this moment it is not clear whether these cells have similar biochemical and genomic profiles. MDSCs generated from hematopoietic progenitors also have the same issue 51, 52 . The generation of suppressive neutrophils in vitro is a more difficult task, probably because of their nature as terminally differentiated cells and their very short survival in culture. However, neutrophils isolated from the blood of healthy donors acquire potent suppressive activity after treatment with ER-stress inducers 36 . M-MDSCs are more suppressive than PMN-MDSCs on a per-cell basis 22, 34 . PMN-MDSCs and M-MDSCs use different mechanisms to suppress immune responses, and some of the mediators of Immune suppression -
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suppression can be used to distinguish MDSCs from neutrophils and monocytes. The most prominent factors implicated in MDSC suppressive activity include ARG1, NO, upregulation of ROS, and the production of prostaglandin E2 (PGE2) [53] [54] [55] . Changes in oxidative phosphorylation and glycolysis in tumors have also been associated with the function of MDSCs. In mice, glycolysis increases concurrently with increased ARG1 activity in MDSCs. Interestingly, AMP-activated protein kinase is also activated and normally drives metabolism toward oxidative phosphorylation 56 . A very recent study showed that tumor-infiltrating MDSCs preferentially use fatty acid-β oxidation (FAO) as a primary source of energy. Tumorinfiltrating MDSCs show increased mitochondrial mass, expression of key FAO-associated genes, and an increased oxygen-consumption rate 57 . Inhibition of FAO affects the suppressive functions of MDSCs and enhances the efficacy of cancer immune therapy.
The stress response of ER has emerged in recent years as an important mechanism regulating the pathologic activation of MDSCs, and thus is critical for the functions of these cells. The ER stress response is an evolutionarily conserved mechanism used by cells for protection from dysregulated proliferation, oxidative stress, nutrient deprivation, hypoxia and acidic extracellular pH. Three major sensors of ER stress are currently described: protein kinase RNA-like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF6). The transcription factor CHOP is a critical mediator of the PERK pathway, whereas spliced X-box binding protein-1 (sXBP1) is a mediator of the IRE1 pathway 58, 59 . In tumor DCs, ER stress leads to increased lipid peroxidation and is directly implicated in defective function in these cells 60 . MDSCs from tumor-bearing mice and from humans with cancer demonstrate a much greater ER stress response than neutrophils and monocytes from tumor-free hosts 61 . Upregulation of the PERK and IRE1 pathways has been observed. The level of ER stress response at the tumor site is substantially higher than that in peripheral lymphoid organs in mice 61 . The direct cause of ER stress induction in MDSCs is not clear. However, the functional consequences have been identified. Experimental induction of ER stress enhances the immunosuppressive capacity of tumor-infiltrating MDSCs by increasing expression of Arg1, Nos2 and Nox2 (Cybb) 62 . Tumor MDSCs from CHOP-deficient mice show low expression of phosphorylated STAT3 and decreased production of IL-6 and ARG1, which are directly involved in immune suppression. CHOPdeficient MDSCs isolated from tumor-bearing mice have reduced immunosuppressive activity 63 . Increased amounts of sXBP1 were observed in human LOX-1 + PMN-MDSCs as compared with the levels in LOX-1 -neutrophils 36 . Moreover, the induction of ER stress in neutrophils isolated from healthy donors converts the neutrophils to potent suppressive cells 36 . ER stress also controls MDSC survival in tumors and favors apoptosis through TNF-related apoptosis-induced ligand receptor 2 and caspase-8 activation 61 . In fact, targeting of the proapoptotic molecule TRAIL-R2 results in the elimination of different populations of MDSCs without effects on mature myeloid or lymphoid cells in people with cancer 64 . Another study showed that trabectedin, an approved chemotherapeutic agent, induces apoptosis of monocytes and macrophages by activating the extrinsic apoptotic pathway downstream of TRAIL receptors 65 . Consistent with these observations, the absence of CHOP was shown to delay apoptosis and prolong survival of MDSCs in cancer 63 . Other mechanisms of MDSC-mediated immune suppression include upregulation of regulatory T cells and immune suppressive cytokines; these are reviewed in detail elsewhere 2 . Together, these unique features of MDSCs allow for the identification of these cells and provide insight into their biological activity.
How important is the immature state for MDSC biology?
One of the controversial questions of MDSC biology is whether all MDSCs are immature cells. A large number of studies in mice and humans have demonstrated that most PMN-MDSCs have a morphology similar to that of immature granulocytes, and in some in vitro studies PMN-MDSCs were able to acquire characteristics of mature neutrophils after short-term culture 16 . However, a recent study showed that granulocytic MDSC populations in people with Hodgkin's lymphoma were composed mostly of mature low-density suppressive neutrophils in an activated state 66 . Another recent study confirmed that activated mature neutrophils expressing CD10, isolated from human subjects with systemic lupus erythematosus and cancer and from G-CSF treated donors, also have suppressive properties 67 . Although more studies are needed to clarify this issue, it is likely that pathologic activation of PMN-MDSCs would include mature cells.
In tumor tissues, M-MDSCs rapidly differentiate into TAMs and inflammatory DCs 27, 61 . These terminally differentiated myeloid cells can persist in tissues for a long time. TAMs have a long-established role as inhibitors of immune responses and promoters of tumor progression 68, 69 . Some studies have shown that inflammatory DCs can promote antitumor T cell responses 70, 71 . However, it also has been shown that they can contribute to immune suppression in tumor-bearing hosts 72 .
Do MDSCs have similar roles in different pathologic conditions?
Cancer was historically the first condition in which MDSCs were described. Below we discuss the data that directly implicate MDSCs in clinical outcome and response to therapy. In recent years, a large body of evidence demonstrated the role of MDSCs in the regulation of immune responses and the pathogenesis of many pathologic conditions. The question is whether these MDSCs have similar origins and functions. No direct side-by-side comparisons have been carried out so far. However, analysis of available data (below) may clarify this question.
Cancer
The role of MDSCs in mouse tumor models is well established 15 . In most studies reported so far, PMN-MDSC populations expanded much more than M-MDSC populations. In recent years, the clinical role of MDSCs has emerged. Initial studies monitored MDSCs in people with cancer, analyzing the total MDSC population (PMNMDSCs and M-MDSCs together). Results showed positive correlation of MDSC numbers in peripheral blood with cancer stage and tumor burden in colorectal carcinomas and in breast, bladder, thyroid and non-small-cell lung cancer (NSCLC) [73] [74] [75] [76] [77] [78] [79] . In melanoma and breast cancer, both PMN-MDSC and M-MDSC numbers correlate with stage and metastasis 80 . In a meta-analysis, elevated numbers of MDSCs in the circulation were found to be an independent indicator of poor outcomes in subjects with solid tumors 81 . Accumulation of M-MDSCs in peripheral blood was associated with shorter progression-free interval and/or overall survival in subjects with NSCLC or with colorectal, bladder, thyroid, uterine or cervical cancer [77] [78] [79] [82] [83] [84] . In melanoma and hepatocellular carcinoma, higher numbers of both PMN-MDSCs and M-MDSCs are correlated with poorer outcomes compared with those for subjects with low numbers of these cells 80, 85 . In non-solid tumors, M-MDSC numbers correlate with reduced survival in subjects with multiple myeloma, Hodgkin's or non-Hodgkin's lymphoma, and diffuse large B cell lymphoma 66, 86, 87 . Notably, most studies have considered only circulating MDSCs, but some attention should also be paid to tumor-infiltrating cells. In one report, neutrophil (CD66b Recent studies demonstrated the value of MDSCs in predicting the response to various cancer therapies. The frequency of M-MDSCs is negatively correlated with the response to chemotherapy in breast, cervical, prostate and colorectal cancer 76, 82, 84, 90 ; squamous cell carcinoma; multiple myeloma; and Hodgkin's lymphoma [91] [92] [93] . Similarly, PMN-MDSC numbers are negatively correlated with chemotherapy response in colorectal cancer 82 . High M-MDSC numbers are a predictor of radiotherapy failure in hepatocellular carcinoma 75, 94 . High numbers of circulating MDSCs have been associated with vaccine failure in subjects with melanoma, NSCLC and colon adenocarcinoma 95, 96 . The percentage of circulating M-MDSCs and PMN-MDSCs is negatively correlated with objective clinical response to ipilimumab (anti-CTLA-4) in patients with unresectable melanoma [97] [98] [99] . Moreover, in melanoma patients, M-MDSC frequency predicted the failure of second-line immunotherapy with anti-PD1 (nivolumab) after failure of first-line ipilimumab treatment 100 . Recent studies in mouse tumor models showed that inhibition of MDSCs during immunotherapy increases therapeutic effect [101] [102] [103] [104] [105] [106] .
Infectious diseases
Many studies have shown that bacteria (both Gram-positive and Gram-negative) can induce or modulate MDSCs both in vitro and in vivo (reviewed elsewhere 107 ). In some studies, subpopulations of MDSCs were not analyzed in detail; thus we refer to those studies with the broader definition of "MDSC. "
In Staphylococcus aureus infection models, M-MDSC and PMN-MDSC populations expand and suppress T cells 108 , thereby contributing to the aggravation of infection 109 . Mycobacterium tuberculosis induces the expansion of PMN-MDSC and M-MDSC suppressive activity in mice 110 . Humans with sepsis show increased numbers of MDSCs; PMN-MDSC populations are expanded mainly in cases of sepsis caused by Gram-positive pathogens, whereas M-MDSC populations expand in response to Gram-positive or Gram-negative pathogens 111 . Sepsis-associated MDSCs have upregulated ARG1 expression and are associated with adverse outcome 112 . However, the expansion of MDSC populations after bacterial infection does not always translate to worse outcomes. In Pseudomonas aeruginosa and Klebsiella pneumoniae infection, expanded MDSC populations are associated with host protection and better outcomes 113 . It seems that in early stages of sepsis (and probably in other infections as well) the accumulation of neutrophils and monocytes with potent antipathogen activity protects the host. MDSCs are probably either not present or present at very low frequency. However, if infection is not resolved, the frequency of MDSCs increases gradually, and these cells exert an immune-suppressive effect on adaptive immunity, which is very similar to the situation observed in cancer.
Human pathogenic fungi have been observed to regulate the immune system and directly induce MDSC accumulation. In those studies, MDSCs were monitored as Gr1
+

CD11b
+ cells, without further . In a followup study, the same group demonstrated that MDSC induction and suppressive activity on T cells during Candida infection depend on the Candida species 115 . MDSC populations were observed to expand in mouse and rat models of Pneumocystis pneumonia infection, in which MDSCs exert their function through ARG1 and iNOS and contribute to increased severity of infection 116 . M-MDSC populations are expanded in people with chronic hepatitis C virus (HCV) infection. This cell accumulation correlates with disease progression and response to antiviral therapy 117 . Different studies report ROS production 118 or ARG1 117 as the main mechanism for MDSC-mediated T cell suppression. HCV-induced MDSCs can directly inhibit NK cell activities via ARG1-independent mechanisms 119, 120 . In vitro studies show that HCV directly induces M-MDSCs through TLR2-STAT3 signaling. These MDSCs stimulate the accumulation of regulatory T cells (T reg cells) and inhibit the proliferation of CD4 + T cells 121 . M-MDSC populations are also expanded in HIV-1-infected individuals, and suppress T cell function via ARG1 122, 123 . Similarly to HCV, HIV directly induces the expansion of M-MDSC populations 124 that promote the differentiation of T reg cells 125 . PMNMDSCs may induce T cell anergy by suppressing CD3-ζ expression and inhibiting CD8
+ T cells through PD-L1-PD1 interaction 123, 126 . PMN-MDSC accumulation in people with primary HIV-1 infection may be regulated by TRAIL and GM-CSF, and positively correlates with disease progression 126, 127 . Thus, the accumulation, functional activity and major biochemical features of MDSCs in infectious disease closely resemble those of cancer-associated MDSCs.
autoimmune disorders
In cancer and infectious disease MDSC activity is deleterious for patients, but the role of MDSCs in autoimmune disease is more complex. It has been shown that MDSC populations are expanded in murine models of and humans with autoimmune diseases 128 . Nevertheless, the role of MDSCs in this process is not established, and contrasting studies show positive and negative roles for MDSCs in the regulation of disease progression. Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder with high cellular infiltration of organs. In mouse models, MDSCs suppressed CD4 + T cell proliferation via ARG1, and MDSC populations expanded in peripheral blood and kidney during disease progression 129 . The ability of MDSCs to expand regulatory B cell populations has also been demonstrated 130 . However, in lupus-prone mice MDSC function was found to be impaired, which suggests that SLE development is associated with a defect in MDSCs Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to inflammation of multiple joints and can progress to cartilage destruction and bone erosion. Initial studies in a mouse collagen-induced arthritis (CIA) model showed that suppressive MDSCs accumulate in the spleen, and adoptive transfer of MDSCs reduces the severity of RA by blocking the CD4 + T cell proinflammatory immune response 133 . In that study, MDSCs lost suppressive activity during arthritis development, and thus were not able to control the disease 133 . M-MDSCs isolated from BM of CIA mice were also able to inhibit B cell proliferation and function, thereby improving CIA outcome 134 . In support of a beneficial role of MDSCs in RA models, synovial fluid of individuals with RA was found to contain PMNMDSCs that were able to suppress T cell activity in vitro 135 , similar to what was previously shown in mice 136 . Moreover, the number of circulating MDSCs in people with RA negatively correlates with the number of T H 17 cells and with plasma arginin concentrations 137 . Recently, it has been reported that MDSCs could have the opposite role and promote RA onset in mice by sustaining T H 17 cell differentiation. MDSC infiltration in arthritic joints positively correlates with high disease activity, but MDSC frequency in peripheral blood negatively correlates with T H 17 cell numbers 134 . Overall, RA studies consistently report beneficial effects of adoptive transfer of MDSCs for inhibiting RA progression in mouse models, consistent with the suppressive activity of these cells, but MDSC recruitment shows inconsistent effects with regard to the expansion of T H 17 cell and T reg cell populations and to RA onset. This inconsistency could be due to the heterogeneity of the myeloid cell population discussed above, with variable frequencies of MDSCs present among the total population of myeloid cells. Several studies have also associated MDSCs with inflammatory bowel disease. MDSCs reduce the severity of experimentally induced colitis in mice 138 . In a study involving people with inflammatory bowel disease, populations of cells with the M-MDSC phenotype were expanded. However, these cells did not suppress T cell function 139 . Thus, the importance of MDSCs in autoimmune diseases is evident. However, compared with what is observed in cancer and infectious diseases, the expansion of MDSC populations in autoimmune disease states is less prominent; this results in greater heterogeneity of the myeloid population and variable frequency of MDSCs among myeloid cells, which may in turn lead to contradictory results. This heterogeneity is apparently due to the different severities of autoimmune diseases and specifics of the microenvironment.
obesity and pregnancy
Obesity is associated with chronic inflammation and with increased risk of breast, prostate and colorectal cancer, as well as cardiovascular and metabolic disorders and type 2 diabetes mellitus 140, 141 . The metabolic changes in the microenvironment associated with obesity and the associated chronic inflammation led to the hypothesis that MDSCs could have a role in maintaining immune homeostasis in obese subjects. In a mouse model of diabetes, MDSCs were able to downregulate immune responses and prevent diabetes onset 142 . Tissue-infiltrating MDSCs are crucial in controlling obesity-associated inflammation and increasing insulin sensitivity. MDSCs suppress CD8 + T cells by iNOS and IFN-γ -dependent mechanisms. MDSCs also induce M2 macrophage polarization, probably through IL-10 143 . Obese subjects are often susceptible to infections and respond poorly to vaccines. This observation could be explained by the expansion of MDSC populations and consequent suppression of T and B cell functions, as demonstrated in obese mice 144 . There are few human studies in the field, but it was reported that M-MDSC numbers were increased in the peripheral blood of obese subjects 145 . Recent work showed that obesity causes the expansion of neutrophil populations in mouse lungs, thus enhancing breast cancer metastasis through IL-5 and GM-CSF activity 146 ( Fig. 3a) . Insulin resistance promotes the development of metabolic syndrome, characterized by elevated levels of serum inflammatory cytokines and high macrophage infiltration in adipose tissue. Macrophages accumulate in adipose tissue as obesity progresses, and in late obesity M2 macrophages are induced in parallel with MDSC infiltration of adipose tissue (reviewed previously 147 ). Insulin resistance could be the result of adaptation to bacterial infection in order to provide glucose to M1 macrophages, which rely on glycolysis. M2 macrophages instead rely on oxidative phosphorylation (reviewed previously 148 ). Increased concentrations of IGF-1 and estrogens associated with insulin resistance and obesity can directly polarize myeloid cells in adipose tissues to the M2 phenotype 149, 150 . The obesity microenvironment can also induce the differentiation of M2 macrophages to M1 macrophages that then recruit T cells 151 and induce monocyte migration via CCL2 152 . In vitro, macrophages from obese subjects or exposed to conditions that mimic the obesity microenvironment show increases in migration and in upregulation of TAM markers 153 . In the same study, it was also demonstrated that obesity promotes macrophage infiltration in the prostate tumor microenvironment and induces TAM polarization through the COX2-PGE2 pathway 153 . Maternal-fetal tolerance is critically important for normal pregnancy. Pregnancy failure (e.g., miscarriage, implantation failure, preterm birth, preeclampsia) is associated with dysregulation of the immune system (reviewed elsewhere 154 ). Early observations in mice showed that MDSCs accumulate in mouse placenta 155 and that their numbers decrease toward the time of delivery. Subsequently, expansion of MDSC populations was observed in peripheral blood and the uterus of pregnant mice, in association with anti-inflammatory functions 156 . MDSC recruitment is driven by CXCR2 157 , and progesterone supports MDSC differentiation and activation via STAT3 signaling 158 . MDSCs suppress T cells via either ARG1 159 or ROS production 158 or by preventing T cell activation by downmodulating L-selectin expression on naive T cells 160 . MDSC populations are expanded in the peripheral blood 161 and decidua 162 during pregnancy in healthy women, and rapidly decrease to normal levels after birth 163 . Reduced numbers of MDSCs in peripheral blood, endometrium and placenta are associated with early miscarriage 164 , and low levels of arginine and reduced iNOS expression in placental tissues are found in women with preeclampsia 165, 166 . A study demonstrated that MDSC populations are expanded during the first trimester and decrease toward the third trimester 164 . Conversely, a different study showed that MDSC populations are equally expanded during the entire gestation period 163 . In that study, the main population of MDSCs observed to be expanded in peripheral blood was PMN-MDSCs, expressing ARG1 and iNOS and producing high levels of ROS 163 . During pregnancy, estradiol expands M-MDSC populations in the circulation via STAT3 activation that suppresses T cells in an ROS-dependent fashion 158 . Conversely, in placental tissue, M-MDSC populations were observed to be expanded by CCL2 and to overexpress IDO1, ARG1 and COX2 166 . PMN-MDSCs in the placenta can also interact with other immune-system cell populations, directly expanding T reg cell populations via the TGF-β -β -catenin pathway 159 ( Fig. 3b) . The expansion of MDSC populations is rapidly canceled in postpartum women, but MDSC populations are expanded in neonates during the first month of life. In neonates, the expanded MDSC populations consist mainly of PMN-MDSCs that suppress T cells in a contact-dependent manner and reduce IFN-γ production. Numbers of PMN-MDSCs decrease rapidly in the first 6 weeks of life and reach adult levels by the time the infant is 6 months of age 167 .
In the same studies, PMN-MDSC populations were expanded in the cord blood (CB), where the cells' frequency correlated with the proliferative capacity of T cells after stimulation in vitro. Expansion of M-MDSC and PMN-MDSC populations in CB modulated the adaptive immune response 168 . PMN-MDSCs from CB directly inhibited type 1 helper T cell responses and induced type 2 helper T cell responses and T reg cells. In this setting PMN-MDSCs mediated suppression via the expression of ARG1 and iNOS, the production of ROS, and the degradation of tryptophan by IDO expression 169 . PMN-MDSCs in neonates show reduced apoptosis and immunosuppressive activity after infection with Escherichia coli 170 . A recent study showed that M-MDSC populations are expanded in neonates and respond to microbial stimulation 171 . Mouse studies by the same group showed that S100A8/A9 prevents the expansion of these cell populations and prevents death from septic shock 171 . Studies in humans showed that S100A9 secretion protects neonates from sepsis by regulating MyD88-dependent gene programs 172 . Thus, MDSCs in pregnancy mainly follow the pattern observed in cancer and are apparently one of the important regulators of fetal-maternal tolerance. Because of limited information, at this time the biological role of MDSCs in newborns is not clear. It is possible that MDSCs have evolved as a protective mechanism to limit inflammation associated with bacterial colonization of the gut.
Conclusions
MDSCs are now recognized as one of the major negative regulators of immune responses in many pathologic conditions. The challenge is to identify specific markers of these cells that allow for easy phenotypical distinction of MDSCs from neutrophils and monocytes in mice, and to expand the already existing panel of markers in humans. This would allow for better understanding of the biology of these cells. It appears that in contrast to T reg cells or checkpoint molecules, MDSCs are not present in steady-state conditions. This provides a unique opportunity to target these cells without possible side effects. Understanding the molecular mechanisms that regulate the accumulation and function of these cells will allow for more precise targeted therapy. The clinical significance of MDSCs in cancer and in some infectious diseases is now established. The next step is to determine whether targeting MDSCs can provide tangible clinical benefits. Work conducted over the next several years will provide an answer to this question.
